CN104774265B - The neutralizing monoclonal antibody 11F1 and its hybridoma cell strain of anti human nerve growth factor - Google Patents
The neutralizing monoclonal antibody 11F1 and its hybridoma cell strain of anti human nerve growth factor Download PDFInfo
- Publication number
- CN104774265B CN104774265B CN201510073966.2A CN201510073966A CN104774265B CN 104774265 B CN104774265 B CN 104774265B CN 201510073966 A CN201510073966 A CN 201510073966A CN 104774265 B CN104774265 B CN 104774265B
- Authority
- CN
- China
- Prior art keywords
- hole
- monoclonal antibody
- growth factor
- ngf
- neutralizing monoclonal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
" the neutralizing monoclonal antibody 11F1 and its hybridoma cell strain of anti human nerve growth factor " of the invention, is related to field of immunology.The neutralizing monoclonal antibody of anti human nerve growth factor, as secreted by the hybridoma that preserving number is CGMCC No.8773, the neutralizing monoclonal antibody has neutralization reaction effect with growth factor of human nerve, its hypotype of classifying is：Heavy chain IgG1, light chain Kappa.There is specific neutralization activity to growth factor of human nerve, can be as the antagonist of growth factor of human nerve.
Description
Technical field
The present invention relates to field of immunology, more particularly to the monoclonal antibody and its hybridoma of anti human nerve growth factor
Cell line.
Background technology
Nerve growth factor (NGF) is one kind god for having the function of neurotrophic and promoting enation double biological
Through cell growth regulator, its development, differentiation, growth, regeneration and expression of functional characteristic to maincenter and peripheral neurons
It is respectively provided with important regulating and controlling effect.
Research shows that nerve growth factor (NGF) is a kind of in the generation of hypersensitivity and the generation of allodynia
Mediator with key effect.A large amount of preclinical studies show：Prevent the interaction of NGF and its acceptor, you can relieve pain.
NGF monoclonal antibodies are neutralized with NGF, block the interaction of NGF and the acceptor in its sensory neuron so as to reach alleviation pain
The effect of pain.(anti-nerve growth factor monoclonal antibody Tanezumab. pharmacy progress .2010,34 (1):526.).Have been reported that
Display is prevented using Anti-NGF Antibody antagonist or is treated postoperative pain, including from operation or from cutting
Or the pain of traumatic wound.Also have been reported that display anti-ngf antibodies are used to treat various diseases, including asthma, arthritis and silver
(Xie Er anti-ngf antibodies of D.L. are used to treat various disease Chinese Patent Application No. bits disease：02814992.0).However, mesh
The preceding report to Anti-NGF Antibody is research polyclonal antibody (Zhao little Lin, by the eastern Anti-NGF Antibodies that shake mostly
Prepare and its using China Journal of Neuroscience .2004,20 (2):171-173.).And the poor specificity of polyclonal antibody, use
The background that develops the color when immunohistochemistry is high, and quality is difficult to control, it is difficult to is promoted in clinical practice.Monoclonal antibody has specificity
By force, the advantages of sensitiveness is high, is widely used in clinical detection, can be used in a variety of methods such as immunohistochemistry, ELISA.
The research to nerve growth factor monoclonal antibody is not common both at home and abroad.The anti-rhNGF monoclonal antibodies having had been reported that are logical
Cross the NGF (antigens using the salmonella thalline adsorption and purification after acid treatment：Thalline 1：5) intrasplenic injection, splenocyte and marrow
Oncocyte screens after PEG is merged and obtains hybridoma, and the anti-rhNGF monoclonal antibodies to obtaining have carried out preliminary mirror
(Su Jin, Zhang Yali, You Changxuan, wait preparation and Preliminary Identification cells and the molecular immune of anti-human NGF monoclonal's antibody to setting analysis
Learn magazine .2002,18 (2):168), but without the neutralization activity of confrontation rhNGF monoclonal antibodies identified.Therefore, at present
Also need to obtain the high anti-human NGF monoclonal's antibody of a kind of high specificity, neutralization activity, alleviation and disease for Clinical Pain
Treatment.
The content of the invention
According to the demand in above-mentioned field, the present invention provide a kind of anti human nerve growth factor neutralizing monoclonal antibody and
Its hybridoma cell strain.
The claimed technical solution of the present invention is as follows：
The neutralizing monoclonal antibody 11F1 of anti human nerve growth factor, by the hybridization that preserving number is CGMCC No.8773
Secreted by oncocyte, the neutralizing monoclonal antibody has neutralization reaction effect with growth factor of human nerve, its hypotype of classifying is：
Heavy chain IgG1, light chain Kappa.
The hybridoma cell strain of growth factor of human nerve neutralizing monoclonal antibody 11F1 is secreted, its preserving number is CGMCC
No.8773。
This area of research based on to(for) the neutralizing antibody of anti human nerve growth factor, be also claimed above-mentioned antibody with
Under：Pharmaceutical applications：
A kind of analgesic medicine, it is characterised in that：Its effective component includes the neutralizing monoclonal antibody 11F1.
A kind of antiallergy medicament, it is characterised in that：Its effective component includes the neutralizing monoclonal antibody 11F1.
One kind resists antasthmatic medicament, it is characterised in that：Its effective component includes the neutralizing monoclonal antibody
11F1.A kind of medicament for being used to treat psoriasis, it is characterised in that：Its effective component includes the neutralizing monoclonal antibody
11F1。
A kind of method for the neutralization activity for identifying anti-nerve growth factor antibody, step are as follows：
(1) with maintaining culture medium to prepare antibody samples solution, on the basis of 40 μ g/ml of pre-dilution concentration, carrying out 2 times is
Row dilution, totally 9 dilution factors, testing sample solution is transferred in 96 orifice plates, each 3 multiple holes of concentration, per 50 μ l of hole, is selected else
Select 3 holes and add the culture medium without antibody as negative control, per 100 μ l of hole；
9 dilution factors are respectively：10μg/ml、5μg/ml、2.5μg/ml、1.25μg/ml、0.625μg/ml、
0.3125μg/ml、0.15625μg/ml、0.078125μg/ml、0.039063μg/ml；
(2) the another NGF protein solutions for maintaining culture medium to prepare 200ng/ml, add it to containing anti-ngf antibodies sample
In 96 orifice plates of product solution, per 50 μ l of hole, negative control hole does not add NGF culture mediums, alternative to select 3 holes to add positive controls molten
96 orifice plates per 100 μ l of hole, are then positioned over 37 DEG C of incubators and are incubated 1h by liquid 100ng/ml NGF；
(3) amount of taking fully TF-1 cell cultures, are collected by centrifugation TF-1 cells, and PBS is washed 2 times, and the cell being collected by centrifugation is used
Maintain culture medium to be resuspended, be made into every 1ml containing 5 × 104The cell suspension of a cell, is inoculated in 96 porocyte culture plates and contains
In the hole of NGF albumen and anti-ngf antibodies, negative control hole and Positive control wells, per 100 μ l of hole；96 orifice plates are placed in 37 DEG C,
5% carbon dioxide culture；After 72h, 20 μ l of MTS solution are added per hole, in 37 DEG C, when 5% carbon dioxide culture 3 is small；
(4) 96 orifice plates are taken out from incubator, are put into microplate reader, absorbance, record measure knot are measured at wavelength 490nm
Fruit；
(5) by the absorbance of product to be measured, according to formula：The neutralization inhibiting rate (%) in anti-ngf antibodies hole=[(positive
Hole OD490nm average values-negative hole OD490nm average values)-(antibody hole OD490nm average values-negative hole OD490nm is averaged
Value)]/(positive hole OD490nm average values-negative hole OD490nm average values), the neutralization inhibiting rate per hole is calculated, neutralizes and suppresses
Rate is higher, then the neutralization activity of anti-ngf antibodies is stronger.
It is demonstrated experimentally that the neutralizing monoclonal antibody of anti human nerve growth factor provided by the invention can be with people's nerve growth
Factor-specific combines, and has neutralization reaction activity, therefore can be as the antagonist of hNGF.Grown with existing anti human nerve
Factor polyclonal antibody is compared, and monoclonal antibody high specificity provided by the invention, can avoid cross reaction, and provided by the invention
Monoclonal antibody have passed through the identification of neutralization activity, its potency is high, affinity is strong, specificity is good, can occur with growth factor of human nerve
Obvious neutralization reaction.
The hybridoma cell line of the monoclonal antibody of secretion anti human nerve growth factor, its preservation is also claimed in the present invention
Number be respectively CGMCC No.8773.
On the other hand, the present invention also provides a kind of method for the neutralization activity for identifying anti-nerve growth factor antibody, institute
It is TF-1 cell proliferation methods to state method.The present invention, should first using the neutralization activity of TF-1 cell proliferation methods detection anti-ngf antibodies
Method can accurately and efficiently detect the neutralization activity of anti-ngf antibodies, its principle is：The TF-1 cells that NGF is relied on are in NGF
It can promote TF-1 cell Proliferations under the conditions of albumen is existing, but after it with the addition of certain density anti-ngf antibodies, anti-NGF
With NGF neutralization occurs for antibody, so as to suppress the good growth of TF-1 cells, then by adding MTS mixed solvent cells
Colour developing, surveys absorbance in microplate reader at OD490nm, calculate the neutralization inhibiting rate per hole, neutralization inhibiting rate is higher, and anti-NGF resists
The neutralization activity of body is also stronger.
Biological deposits information：
Biomaterial title：12C11
Classification And Nomenclature：Mouse hybridoma cell
Preservation date：On January 16th, 2014
Preserving number:CGMCC No.8772
Preservation mechanism：China Committee for Culture Collection of Microorganisms's common micro-organisms center
Address：Yard 1, BeiChen xi Road, Chaoyang District, Beijing City 3, Institute of Microorganism, Academia Sinica
Biomaterial title：11F1
Classification And Nomenclature：Mouse hybridoma cell
Preservation date：On January 16th, 2014
Preserving number:CGMCC No.8773
Preservation mechanism：China Committee for Culture Collection of Microorganisms's common micro-organisms center
Address：Yard 1, BeiChen xi Road, Chaoyang District, Beijing City 3, Institute of Microorganism, Academia Sinica
Brief description of the drawings
Fig. 1 immunized mice serum titer testing results
The SDS-PAGE identifications of the monoclonal antibody-purified effects of the anti-hNGF of Fig. 2
The Western Blot results of the anti-hNGF monoclonal antibody proteins of Fig. 3
In the anti-hNGF monoclonal antibodies of Fig. 4 and inhibition assay result
Embodiment
The present invention is described in more detail, it is necessary to which explanation is below by specific embodiment, following embodiments are only
For explanation and illustration, rather than it limit the invention in any way.
Experiment material：
BALB/c mouse：Purchased from Department Of Medicine, Peking University's Experimental Animal Center.
rhNGF：Recombinant human nerve growth factor, expressed by applicant's unit and purify (happy big, Peng Lujia, history authority,
Deng the high efficient expression and biological evaluation research Chinese Pharmaceutical Affairs .2014 of recombinant human nerve growth factors, 28 (6)：601-
606.)。
The TF-1-A2 cells that NGF is relied on：By TF-1 cell (Liu of applicant's unit our company domestication rear cloneization screening
In lotus, find pleasure in big, Huo Lihong, waits subcloned cells strains TF-1-A2 and preparation method thereof and purposes Chinese invention patent grant numbers：
ZL 2012 1 0119401.X.)。
Injection mouse nerve growth factor (Soviet Union's peptide life, Beijing SHUTAISHEN pharmaceutcal corporation, Ltd, lot number：201211148)
The sheep anti-mouse igg of AP marks：Purchased from SIGMA companies (Cat.No.:A3562).
The not specified experiment reagent of the present invention is this area conventional reagent, can be by commercially available or using this area
Conventional method is prepared, and specification is the pure level of experiment.
The preparation of the anti-hNGF monoclonal antibodies of embodiment 1.
1st, BALB/c mouse is immunized
It is prepared by rhNGF：Voluntarily express, purify and prepare that (happy big, Peng Lujia, history authority, waits recombined humans refreshing by applicant
High efficient expression and biological evaluation research Chinese Pharmaceutical Affairses .2014 through growth factor, 28 (6)：601-606.).
5 female BAl BIcs/c mouse are chosen, rhNGF antigens are mixed with Freund's complete adjuvant (sigma companies), have been emulsified
It is subcutaneously injected after complete, the immunizing dose of every mouse is immunized for 80 μ g.After first immunisation, it is spaced 2 weeks and 3 weeks, by rhNGF antigens
Repeat to be immunized twice after being emulsified with not formula Freund's incomplete adjuvant (sigma companies), mouse tail takes blood, with indirect ELISA side
Method detects the potency (the results are shown in Figure 1) of serum specific antibody, and wherein 2# Mouse titers are up to 1：104, respectively to 1#,
2#, 3#, 4# and 5# mouse carry out test for fusion.3 days before fusion, abdominal cavity booster immunization 1 time.
2nd, the preparation of hybridoma
Take the spleen of immune BALB/c mouse to be developed into splenocyte suspension under gnotobasis in super-clean bench, trained with RPMI1640
Support base to wash 2 times, collect 1 × 108Splenocyte and 2 × 107-5×107Myeloma cell SP2/0 is mixed in a 50ml fusion pipe
In, RPMI1640 culture mediums are added to 30ml, are fully mixed.1000r/min is centrifuged 10 minutes, and supernatant is exhausted as far as possible.In hand
Palm touches bottom of fusion pipe, makes sedimentation cell loosely uniform.Added with 1ml suction pipes at 1 minute or so be preheated to 37 DEG C 50%
PEG2000 (PH 8.0) 1ml, side edged gently rotate, and naked eyes are visible particle appearance, is slowly added to RPMI1640 culture mediums extremely
20ml.1000r/min is centrifuged 6 minutes, supernatant discarding.Cultivated in HAT selective mediums within first 10 days, afterwards until the
Cloning selects HT medium cultures before completing.It is thin with indirect enzyme-linked immunosorbent assay (ELISA method) detection fusion after 2 weeks
The positive rate of born of the same parents, selects the higher hole of positive value, the positive hybridoma cell detected is cloned through limiting dilution, continuously
Cloning makes for 3 times the positive rate in positive colony hole select the high hole turn hole of value up to after twice 100% and expand culture and freeze.
The hybridoma cell strain of the anti-hNGF monoclonal antibodies of stably excreting is obtained, its numbering is 11F1 and 12C11, send preservation, preservation
Number be respectively：CGMCC No.8772 and CGMCC No.8773.
3rd, the preparation of anti-hNGF monoclonal antibodies ascites, titer of ascites measure and antibody purification
Using inducing method largely prepares monoclonal antibody in vivo.Take the healthy Balb/c female mices of 6-8 week old, abdominal cavity note
Penetrate paraffin (0.5ml/ is only).After 1 week, hybridoma centrifuge washing, cell number is adjusted to 1 × 10 with PBS6A/ml is every small
Mouse injects 0.5ml.After 5~7d, after mouse web portion expands, gather ascites and titer of ascites is detected.After ascites centrifugation
Supernatant is collected, with Protein A Sepharose antibody purifications.Packing is after -70 DEG C of preservations.
The anti-hNGF monoclonal antibodies subgroup identification of embodiment 2.
Using the Rapid ELISA Mouse Antibody Isotyping Kit (Cat.No. of Pierce companies:
37503) class and subclass of monoclonal antibody are identified, is operated according to kit specification.
The qualification result of the anti-hNGF monoclonal antibodies hypotype of table 1
The anti-hNGF monoclonal antibodies affinity constant measure of embodiment 3.
Using the method for capture antibody, detected with GE companies biomolecular interaction analysis instrument Biacore 3000 anti-
The affinity and binding kinetics of hNGF monoclonal antibodies.
2 Biacore of table detects anti-hNGF monoclonal antibodies and the affinity of rhNGF antigens
The specificity identification of the anti-hNGF monoclonal antibodies of embodiment 4.
The specificity of monoclonal antibody is identified using Western Blot.The purifying effect of anti-hNGF monoclonal antibody proteins
Fruit identifies (Fig. 2) with SDS-PAGE, with Gel-blot-pro analytical electrophoresis bands the result shows that, antibody purity is not less than
90%.SDS-PAGE electrophoresis is carried out to rhNGF and mNGF, after electricity transfer, is incubated with the monoclonal antibody (1 μ g/ml) of preparation, AP marks
The sheep anti-mouse igg (1: 5000 dilution) of note is used as secondary antibody, is operated by the general step of Western Blot.Anti- hNGF monoclonals resist
The Western Blot experimental results of body protein as shown in figure 3, due between the NGF and mouse NGF of people homology be up to
89.1%, and there are data to show between people and mouse NGF there are immunological cross-reaction, therefore in the Western qualification processes also
Identical result is arrived.There are faint cross reaction with mNGF for anti-hNGF monoclonal antibodies.
The anti-hNGF monoclonal antibodies neutralization activity detection of embodiment 5.
The principle of NGF propagation, the monoclonal antibody of the anti-hNGF of this experiment can be relied on according to the NGF TF-1 cells relied on
The biological activity of rhNGF albumen is neutralized, so as to suppress TF-1 cell Proliferations.
Specific experiment step is as follows：
1) with maintaining culture medium to prepare anti-hNGF monoclonal antibodies sample solution, on the basis of 40 μ g/ml of pre-dilution concentration
On, carry out 2 times and be serially diluted, totally 9 dilution factors, detected sample solution is transferred in 96 orifice plates, and each concentration 3 is multiple
Hole, it is alternative to select 3 holes addition negative control solutions (maintenance culture medium) per 50 μ l of hole, per 100 μ l of hole.
2) another with maintaining culture medium to prepare rhNGF protein solutions, concentration 200ng/ml, rhNGF protein solutions are transferred to
In 96 orifice plates containing anti-hNGF monoclonal antibodies sample solution, 3 multiple holes are per 50 μ l of hole.Negative control hole do not add containing
The nutrient solution of rhNGF albumen.It is alternative to select 3 blank wells addition positive control solution rhNGF protein solution 100ng/ml, per hole
100μl.After two step end of operation of the above, 96 orifice plates are positioned over 37 DEG C of incubators and are incubated 1h.
3) amount of taking fully TF-1-A2 cell cultures, are collected by centrifugation TF-1-A2 cells, and PBS is resuspended 2 times, and cell is collected by centrifugation
After be resuspended in and maintain culture medium to be made into every 1ml containing 5 × 104The cell suspension of a cell, is inoculated in 96 porocyte culture plates and contains
There are hole, negative control hole and the Positive control wells of anti-hNGF monoclonal antibodies and rhNGF albumen, per 100 μ l of hole.37 degree are placed in,
5% carbon dioxide culture.After 72h, 20 μ l of MTS solution are added per hole, in 37 degree, when 5% carbon dioxide culture 3 is small.From culture
96 orifice plates are taken out in case, are put into microplate reader, absorbance is measured at wavelength 490nm, record measurement result.According to formula：It is anti-
The neutralization inhibiting rate (%) in hNGF monoclonal antibodies hole=(50ngNGF OD490nm- negative holes value)-(antibody hole
OD490nm- negative holes value)/(50ngNGF OD490nm- negative holes value) calculating neutralization inhibiting rate.
The results are shown in Figure 4, with the increase of anti-hNGF MAb concentrations, the neutralization suppression of anti-hNGF monoclonal antibodies
Rate processed is also continuously increased, and when antibody reaches a certain concentration, neutralizes inhibiting rate and plateau occurs.As shown in table 3,11F1 and
The neutralization inhibiting rate of 12C11 is up to 100%, shows that anti-hNGF monoclonal antibodies and rhNGF albumen have obvious neutralization reaction
Effect.
The anti-hNGF monoclonal antibodies of table 3 are per hole inhibiting rate (%)
Claims (7)
1. the neutralizing monoclonal antibody 11F1 of anti human nerve growth factor, by the hybridoma that preserving number is CGMCC No.8773
Secreted by cell, the neutralizing monoclonal antibody has neutralization reaction effect with growth factor of human nerve, its hypotype of classifying is：
Heavy chain IgG1, light chain Kappa.
2. secreting the hybridoma cell strain of growth factor of human nerve neutralizing monoclonal antibody 11F1, its preserving number is CGMCC
No.8773。
A kind of 3. analgesic medicine, it is characterised in that：Its effective component includes the neutralizing monoclonal antibody described in claim 1
11F1。
A kind of 4. antiallergy medicament, it is characterised in that：Its effective component includes the neutralizing monoclonal antibody described in claim 1
11F1。
A kind of 5. antasthmatic medicament, it is characterised in that：The neutrality monoclonal that its effective component includes described in claim 1 resists
Body 11F1.
A kind of 6. medicament for being used to treat psoriasis, it is characterised in that：Its effective component includes the neutrality described in claim 1
Monoclonal antibody 11F1.
A kind of 7. neutralization activity for the neutralizing monoclonal antibody 11F1 for identifying the anti human nerve growth factor described in claim 1
Method, step is as follows：
(1) with maintaining culture medium to prepare antibody samples solution, on the basis of 40 μ g/ml of pre-dilution concentration, it is dilute that 2 times of series are carried out
Release, totally 9 dilution factors, testing sample solution is transferred in 96 orifice plates, each 3 multiple holes of concentration are alternative to select 3 per 50 μ l of hole
A hole adds the culture medium without antibody as negative control, per 100 μ l of hole；
9 dilution factors are respectively：10μg/ml、5μg/ml、2.5μg/ml、1.25μg/ml、0.625μg/ml、0.3125μ
g/ml、0.15625μg/ml、0.078125μg/ml、0.039063μg/ml；
(2) the another NGF protein solutions for maintaining culture medium to prepare 200ng/ml, add it to molten containing anti-ngf antibodies sample
In 96 orifice plates of liquid, per 50 μ l of hole, negative control hole does not add NGF culture mediums, alternative to select 3 holes addition positive control solutions
96 orifice plates per 100 μ l of hole, are then positioned over 37 DEG C of incubators and are incubated 1h by 100ng/ml NGF；
(3) amount of taking fully TF-1 cell cultures, are collected by centrifugation TF-1 cells, and PBS is washed 2 times, and the cell being collected by centrifugation maintains
Culture medium is resuspended, and is made into every 1ml containing 5 × 104The cell suspension of a cell, is inoculated in 96 porocyte culture plates and contains NGF eggs
In the holes of bletilla anti-ngf antibodies, negative control hole and Positive control wells, per 100 μ l of hole；96 orifice plates are placed in 37 DEG C, 5% dioxy
Change carbon culture；After 72h, 20 μ l of MTS solution are added per hole, in 37 DEG C, when 5% carbon dioxide culture 3 is small；
(4) 96 orifice plates are taken out from incubator, are put into microplate reader, absorbance is measured at wavelength 490nm, record measurement result；
(5) by the absorbance of product to be measured, according to formula：Neutralization inhibiting rate (%)=[(the positive hole in anti-ngf antibodies hole
OD490nm average values-negative hole OD490nm average values)-(antibody hole OD490nm average values-negative hole OD490nm is averaged
Value)]/(positive hole OD490nm average values-negative hole OD490nm average values), the neutralization inhibiting rate per hole is calculated, neutralizes and suppresses
Rate is higher, then the neutralization activity of anti-ngf antibodies is stronger.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510073966.2A CN104774265B (en) | 2015-02-12 | 2015-02-12 | The neutralizing monoclonal antibody 11F1 and its hybridoma cell strain of anti human nerve growth factor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510073966.2A CN104774265B (en) | 2015-02-12 | 2015-02-12 | The neutralizing monoclonal antibody 11F1 and its hybridoma cell strain of anti human nerve growth factor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104774265A CN104774265A (en) | 2015-07-15 |
| CN104774265B true CN104774265B (en) | 2018-05-04 |
Family
ID=53616057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510073966.2A Expired - Fee Related CN104774265B (en) | 2015-02-12 | 2015-02-12 | The neutralizing monoclonal antibody 11F1 and its hybridoma cell strain of anti human nerve growth factor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104774265B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230220057A1 (en) * | 2020-05-27 | 2023-07-13 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Antibodies specifically recognizing nerve growth factor and uses thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1790024A (en) * | 2004-12-16 | 2006-06-21 | 浙江永宁制药厂 | Protein content determination method for nerve growth factor and application thereof |
| CN1849138A (en) * | 2003-07-15 | 2006-10-18 | 安姆根有限公司 | Human anti-NGF neutralizing antibodies as selective ngf pathway inhibitors |
| CN101827609A (en) * | 2007-08-10 | 2010-09-08 | 里珍纳龙药品有限公司 | High affinity human antibodies to human nerve growth factor |
| CN102660505A (en) * | 2012-04-20 | 2012-09-12 | 北京华安科创生物技术有限公司 | Subcloned cell strain TF-1-A2, preparation method thereof and application |
| CN103764677A (en) * | 2011-05-06 | 2014-04-30 | Nvip私人有限公司 | Anti-nerve growth factor antibodies and methods of preparing and using the same |
-
2015
- 2015-02-12 CN CN201510073966.2A patent/CN104774265B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1849138A (en) * | 2003-07-15 | 2006-10-18 | 安姆根有限公司 | Human anti-NGF neutralizing antibodies as selective ngf pathway inhibitors |
| CN1790024A (en) * | 2004-12-16 | 2006-06-21 | 浙江永宁制药厂 | Protein content determination method for nerve growth factor and application thereof |
| CN101827609A (en) * | 2007-08-10 | 2010-09-08 | 里珍纳龙药品有限公司 | High affinity human antibodies to human nerve growth factor |
| CN103764677A (en) * | 2011-05-06 | 2014-04-30 | Nvip私人有限公司 | Anti-nerve growth factor antibodies and methods of preparing and using the same |
| CN102660505A (en) * | 2012-04-20 | 2012-09-12 | 北京华安科创生物技术有限公司 | Subcloned cell strain TF-1-A2, preparation method thereof and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104774265A (en) | 2015-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105348390B (en) | Anti-human PCSK9 monoclonal antibodies | |
| DE60123036T2 (en) | ANTHRAX-SPECIFIC ANTIGEN, VACCINES CONTAINING ANTIGEN, ANTHRAX-SPECIFIC ANTIBODIES, AND ITS USES | |
| CN109438576B (en) | Preparation and application of anti-human CD47 monoclonal antibody | |
| CN112980803B (en) | VIM-resistant carbapenemase hybridoma cell strain, monoclonal antibody and application | |
| CN112501131A (en) | anti-IMP (anti-IMP) carbapenemase hybridoma cell strain, monoclonal antibody and application | |
| CN109232734B (en) | Monoclonal antibody specifically binding canine adenovirus, pharmaceutical composition, kit and application thereof | |
| JP2022535808A (en) | Antibody capable of binding to thymic stromal lymphocyte growth factor and use thereof | |
| CN112980804B (en) | KPC (Klebsiella pneumoniae Carbapenemase) resistant hybridoma cell strain, monoclonal antibody and application | |
| CN104910274B (en) | The neutralizing monoclonal antibody 12C11 and its hybridoma cell strain of anti human nerve growth factor | |
| CN102875674B (en) | Anti-tetanotoxin antibody, and preparation method and application thereof | |
| CN106916225A (en) | A kind of monoclonal antibody for detecting N-terminal plasma pro-brain natriuretic peptide levels and its hybridoma cell strain and application | |
| CN106957366A (en) | A kind of C5aR antibody and its preparation method and application | |
| CN103665152A (en) | Canine parvovirus single-domain antibody, and preparation method and application thereof | |
| CN110872349A (en) | Antibodies that bind human IL-4R, methods of making, and uses thereof | |
| CN110272488B (en) | Cat calicivirus monoclonal antibody and application thereof | |
| CN112979817B (en) | Monoclonal antibody for recognizing anti-CLDN 18_2 antibody and preparation method and application thereof | |
| CN104774265B (en) | The neutralizing monoclonal antibody 11F1 and its hybridoma cell strain of anti human nerve growth factor | |
| CN104560885B (en) | A kind of monoclonal antibody for resisting natural cattle gamma interferon, secretes hybridoma cell strain and the application of the antibody | |
| CN114539405B (en) | anti-TIGIT antibodies or antigen-binding fragments thereof | |
| CN114736296B (en) | Antibody and application thereof in promoting skin fibroblast proliferation | |
| CN108640993A (en) | A kind of anti-recombination human basic fibroblast growth factor nano antibody and its application | |
| CN114805579A (en) | Anti-human ACE2 protein monoclonal antibody, nucleic acid molecule and application | |
| CN106543285B (en) | Anti- Ttyh1 monoclonal antibodies and its application | |
| Galkin et al. | New monoclonal antibodies to the Chlamydia trachomatis main outer membrane protein and their immunobiological properties | |
| CN102827279B (en) | Anti-neuroepithelial stem cell protein monoclonal antibody with high titer and high specificity and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210519 Address after: B216, 2nd floor, No.5 Kaifa Road, Haidian District, Beijing 100085 Patentee after: Beijing Furui Junan Technology Co.,Ltd. Address before: No.5 Kaifa Road, Haidian District, Beijing Patentee before: Beijing Hua'an Innovation Biotechnology Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180504 Termination date: 20220212 |